
A paired analysis of the outcome after kidney transplantation in peritoneal (PD) and 
hemodialysis (HD) patients 
Alicja Dębska-Ślizień, Agnieszka Bobkowska-Macuk, Beata Bzoma, Grażyna 
Moszkowska, Anna Milecka, Dariusz Zadrożny, Wojciech Wołyn, Andrzej Chamienia, 
Monika Lichodziejewska-Niemierko, Ewa Król, Zbigniew Śledziński, Bolesław 
Rutkowski 











Please cite this article as: Dębska-Ślizień A, Bobkowska-Macuk A, Bzoma B, Moszkowska G, Milecka A, 
Zadrożny D, Wołyn W, Chamienia A, Lichodziejewska-Niemierko M, Król E, Śledziński Z, Rutkowski B, 
A paired analysis of the outcome after kidney transplantation in peritoneal (PD) and hemodialysis (HD) 
patients, Transplantation Proceedings (2018), doi: 10.1016/j.transproceed.2018.02.104. 
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to 
our customers we are providing this early version of the manuscript. The manuscript will undergo 
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please 
note that during the production process errors may be discovered which could affect the content, and all 
legal disclaimers that apply to the journal pertain. 




licja Dębska-Ślizień (adeb@gumed.edu.pl)1, Agnieszka Bobkowska-Macuk (agar08@wp.pl)1, 
Beata Bzoma (bbzoma@gumed.edu.pl)1, Grażyna Moszkowska (gramos@gumed.edu.pl)2, Anna 
Milecka (amilecka@gumed.edu.pl)3, Dariusz Zadrożny (zadar@gumed.edu.pl)3, Wojciech 
Wołyniec (wwolyniec@gumed.edu.pl) 4, Andrzej Chamienia (achamienia@gumed.edu.pl)5,6, 
Monika Lichodziejewska-Niemierko (lichotek@gumed.edu.pl)7, Ewa Król 
(ekrol@gumed.edu.pl)1, Zbigniew Śledziński (ichir@gumed.edu.pl)3, Bolesław Rutkowski 
(bolo@gumed.edu.pl)1 

epartment of Nephrology, Transplantology and Internal Medicine1, Department of Clinical 
Immunology and Transplantology2, Department of General, Endocrine, and Transplant Surgery3, 
Department of Occupational, Metabolic and Internal Medicine 4, Kidney Transplant Regional 
Waiting List5, Department of General Nursing, Faculty of Medical Sciences6 and Department of 
Palliative Medicine7 














 
 
 

















 
 
 





























 



































 
 
 
 

































 
 
































 
 

































 
 





























 
 
 
































 
 
 



































 
 

































 
 


































 
 



































 
 















 
 
 

Fig 1. Patient survival (Kaplan-Meier) in days for PDP and HDP group of patients 
Fig 2. Death censored graft survival (Kaplan-Meier) in days for PDP and HDP groups 
Fig 3. Graft survival (Kaplan-Meier) in days for PDP and HDP groups 







 
 
PDP 
9 
HDP 
11 
Significance 
ns 



Comorbidities (n) 
Coronary artery disease (treated 
conservatively) 
Coronary artery disease (treated by PTCA) 
Coronary artery disease (treated by CABG) 
Cerebral stroke 
Peripheral artery disease 
Type 1 diabetes mellitus 
Type 2 diabetes mellitus 
viral hepatitis 
6 
4 
2 
2 
15 
5 
HBV-4 
HCV-1 
3 
3 
2 
4 
9 
12 
HBV-1 
HCV-11 
ns 
ns 
ns 
ns 
ns 
ns 
ns 
Fisher Test, 
p<0.05 
ns 
End point 
Graft loss [95% CI] 
Death censored graft loss [95% CI] 
Death [95% CI] 
Immunological characteristics 
Number of HLA mismatches (n) 
Immunosuppressive protocols (n) 
AZA, CsA, P 
AZA, TAC, P, ATG induction 
AZA, CSA, P, ATG induction 
AZA, TAC, P 
MMF, CsA, P 
MMF, TAC, P 
MMF, CsA, P, induction (anti-CD25) 
MMF, TAC, P, induction (anti-CD25) 
MMF, CsA, P, ATG induction 
MMF, TAC, P, ATG induction 
CsA, sirolimus, P, 
CsA, sirolimus, P, ATG induction 
Everolimus, TAC, P, induction (anti- 
CD25) 
THYMO, csa, mmf 
Everolimus, CsA, P, induction (anti-CD25) 
THYMO, TAC, mmf, P 
TAC, sirolimus, P, ATG induction 
No data 


PDG 
0.674 [0.562-0.809] 
0.716 [0.606-0.845] 
0.907 [0.832-0.988] 
HDG 
0.593 [0.470-0.748] 
0.648 [0.520-0.808] 
0.852 [0.760-0.956] 
2.97 
14 
1 
0 
5 
50 
46 
5 
8 
0 
0 
1 
0 
1 
0 
0 
0 
1 
1 
2.94 
16 
2 
1 
3 
35 
51 
2 
10 
2 
2 
0 
1 
2 
1 
4 
1 
0 
0 
0 
0 






 








Pairs (PDP) 
n (%) 
28 (21.05) 
19 (14.28) 
(HDP) 
n (%) 
57 (42.86) 
43 (32.33) 
p<0.05 
p<0.05 

Delayed graft function 
Acute rejection (not biopsy- 
proven) 
Graft vessel thrombosis 
Urological complications 
Cytomegalovirus infection 
(CMV) 
Other infections (mostly 
urinary tract infection) 
New onset diabetes after 
transplantation (NODAT) 
Duration of the first 
hospitalizations 
T-student test, Fisher test; NS, non-significant 
9 (6.7) 
9 (6.8) 
20 (15.0) 
4(3) 
7 (5.3) 
13 (9.8) 
ns 
ns 
ns 

Variables 
PD 
HR (95% CI) 
2.29 (0.70-7.43) 
Bacterial infections (mainly 
UTI) 
Reoperation 
P value 
0.17 








 









 

 
 


 

 



 


 

 


 

 


 

 


 

 


 

 


 

 


 

 


 

 


 

 

 

 

 

 




 
 

 

 

 

 


 
 
after RTx 
CsA 
Induction therapy (ATG, 
Thymoglobulin, 
basiliximab) 
Coronary heart disease 

 



 
 





 


 

 


 


 


 
 
 
 







HR (95% CI) 
7.46 (2.05- 
27.12) 
10.06 (2.73- 
37.03) 
 

Variables 
DGF 
2.95 (0.85- 
10.17) 
0.36 (0.11-1.24) 



Last visit 
(observation 
time 0.5 to 22 

Peritoneal Dialysis Pairs (PDP) 
n=133 
Hemodialysis Pairs (PDP) 
n=133 
8 deaths 
1- lung cancer 
1-myeloma multiplex 
2- cerebral stroke 
1- sclerosing encapsulating 
peritonitis 
1-cns and lung aspergillosis 
1 – colon cancer 
1-no data 
12 deaths 
1- stomach cancer 
1- sepsis 
3- cardiovascular (myocardial 
infarction) 
1-pulmonary embolism 
1-neuroendocrine neoplasm 
5-no data 













 
 
 




























 
 
 
 
 
HR (95% CI) 
0.99 (0.57-1.73) 
P value 
0.98 


 
 



Variables 
PD 
Bacterial infections (mainly 
UTI)# 
Reoperation 
Duration of hospitalization 
after RTx 
CsA 
1.15 (0.36-3.72) 
1.75 (1.08-2.81) 
0.81 
0.02 
# violation of proportional hazards assumption, * assumption of linearity might (seems to) 
be slightly violated 

 



 
 






 
 

 
 


 

 


 


 


 
 


 

 


 

 


 

 


 

 



 


 

 

 

 

 

 

 

 

 

 


 

 


 
 


 

 


 

 


 

 
HR (95% CI) 
2.14 (1.16-3.94) 
P value 
0.01 







 
 

Variables 
DGF 
Duration of 
hospitalization 
after RTx 
SCC one month 
after RTx 
eGFR one 
month after RTx 
Graft vessels 
thrombosis 
93.41 (32.26- 
270.54) 
95.78 (33.94- 
270.32) 

Variables 
PD 
HR (95% CI) 
0.93 (0.56-1.52) 
Bacterial infections (mainly 
UTI) 
Reoperation 
P value 
0.75 









 
 

 

 


 

 




 
 


 

 
 


 

 



 


 

 


 

 


 

 


 

 


 

 


 

 


 

 


 

 


 

 

 

 

 

 
 


 

 

 

 

 

 


Duration of hospitalization 
after RTx * 
CsA 
Induction therapy (ATG, 
Thymoglobulin, basiliximab) 
Coronary heart disease 
1.50 (0.60-3.76) 
1.73 (1.13-2.67) 
0.39 
0.01 
# violation of proportional hazards assumption, * assumption of linearity might (seems to) 
be slightly violated 

Variables 
DGF 
Duration of 
hospitalization 
after RTx 
SCC one month 
after RTx 
Graft vessels 
thrombosis 
DM 
HR (95% CI) 
1.98 (1.16-3.38) 
P value 
0.01 
HR (95% CI) 
1.96 (1.15-3.35) 
P value 
0.01 
63.18 (23.41- 
170.49) 
- 
68.58 (26.10- 
180.19) 
1.88 (1.02-3.45) 

 


 
 
 




 
 

 


 
 

 


 


 


 

 












HR (95% CI) 
0.82 (0.33-2.03) 


 



able 11. Univariate Cox regression analysis of factors related to death 
Univariate model 
Variables 
PD 
Bacterial infections (mainly 
UTI) 
Reoperation 
Duration of hospitalization 
after RTx 
CsA 
Induction therapy (ATG, 
Thymoglobulin, 
basiliximab) 
Coronary heart disease 

 



 
 




 



 
 

 
 


 

 


 


 


 
 


 

 


 

 


 

 


 

 



 

 

 

 

 

 

 

 

 



 

 

 

 

 


 

 


 

 


 

 


 



P value 
0.06 
- 
- 
P value 
0.09 
0.11 
0.02 
able 12. Multivariate Cox regression analysis of factors related to death 
Variables 

Age 
MM 
UTI 
Coronary heart 
disease 
Graft loss 
HR (95% CI) 
1.03 (0.99-1.07) 
- 
- 
4.72 (1.21- 
18.39) 
21.41 (4.93- 
92.88) 
HR (95% CI) 
1.03 (0.99-1.08) 
0.67 (0.41-1.09) 
2.94 (1.19-7.28) 
3.41 (0.85- 
13.69) 
26.45 (6.04- 
115.89) 







 












 
 

A paired kidney analysis was applied to evaluate the impact of dialysis modality on 
post-transplantation follow up in 133 pairs receiving grafts from the same donor. 











 
 
